Shenzhen Venture Capital leads $28m Series B round in China’s Hrain Biotech

Hrain Biotechnology, a Chinese company that specializes in the research and development of tumour immunotherapy technologies, has secured 200 million yuan ($27.97 million) in a Series B round of financing led by Chinese state-backed venture capital firm Shenzhen Venture Capital, it announced on Monday.